ORGANICELL™ REGENERATIVE MEDICINE
Organicell™ has recently received an approval notification from the FDA for its investigational new drug (IND) application investigating their lead product, Zofin™, for patients diagnosed with moderate to severe acute respiratory syndrome (SARS) due to COVID-19 infection. This trial will be the first randomized, double-blinded, placebo-controlled, phase I/II multi-center clinical trial investigating the safety and potential efficacy of perinatal sourced components for COVID-19.
Organicell™ is the leading, fully integrated Regenerative Medicine Company. Our world class research, technology, manufacturing, and clinical development team is focused on creating new regenerative medicine.
We believe that our ground-breaking research in the field of nanotechnology, specifically extracellular vesicles and perinatal-derived nanoparticles, is the next frontier of regenerative therapeutics. Organicell™ is committed to creating life changing and lifesaving therapies for patients.